Blood test to detect returning cancer after treatment of early-stage solid tumors
Tests a tumor DNA blood test for detecting returning cancer after treatment.
Key facts
- Who runs it
- Guardant Health, Inc.
- Where
- Appleton, Aurora, Birmingham, Boston, Broomall, Chandler, Chapel Hill, Cincinnati, Cleveland, Dallas, East Brunswick, Edinburg, Forth Worth, Grand Rapids, Hollywood, Hot Springs, La Jolla, Lakeland, Lewiston, Myrtle Beach, New Orleans, New York, Newport Beach, Philadelphia, Redwood City, Rochester, Rock Hill, Sacramento, Salt Lake City, San Antonio, Shreveport, Toledo, and York, United StatesSee the 33 sitesAlso in 4 other countries, 24 sites
- Trial code
- Registry title
- ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- Status
- Recruiting
- People taking part
- 2,285 people, planned
- Started
- 7 Sept 2021
- Expected to end
- Aug 2030
- Type of study
- Observational, 12 groups
- Treatments tested
- Guardant Reveal
- Record updated
- 14 September 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults treated with the aim of removing early-stage solid tumors. A blood test for tumor DNA is checked against recurrence of the cancer.
- Age
- Older than 18 years.
- Sex
- All sexes can join.
- Disease stage
- Several cancer types in early stages are accepted, for example muscle invasive bladder cancer (stage II-III), non-small cell lung cancer (stage IB-III) and colon cancer (stage II-III). The cancer must be confirmed by tissue examination.
- Earlier treatment
- First treatment was given to remove all of the disease. Participants have at least one blood sample taken 3-12 weeks after surgery, chemotherapy or radiation.
- Biomarker or test result
- Breast cancer cohorts need known hormone receptor and HER2 status. No other test result is asked for.
Main reasons for not taking part
- History of an organ or tissue transplant from another person
- Cancer that is mostly neuroendocrine
- Another cancer diagnosed within 3 years before joining, with some exceptions
- Known distant metastasis at enrolment, with exceptions for limited stage IV melanoma or renal cell carcinoma
The registry criteria, word for word
Show all 24 criteriaShow less
Who can take part
- Age > 18 years old AND
- Initial treatment is given with curative/radical intent AND
- Are planning to undergo regular follow-up and monitoring for cancer recurrence per standard of care at the enrolling site AND
- Provided written informed consent to participate in the study AND
- Are willing to have de-identified clinical data shared with investigators at regular intervals as outlined in the study protocol and informed consent AND
- Are willing to provide blood samples at enrollment and at subsequent clinical visits coinciding with standard of care follow-up, for up to 3 years as outlined in the study protocol and informed consent AND
- Have at least one Landmark blood sample collected. Landmark samples are collected 3-12 weeks after surgery, chemotherapy and/or radiation/chemoradiation as applicable based on the participant's planned treatment regimen
- Have a histologically confirmed Index Cancer that qualifies for inclusion, defined as:; Primary Study Cohorts
- Cohort 1: Cohort 1: Muscle invasive carcinoma of the bladder, ureter, or renal pelvis (stage II-III),
- Cohort 2: Cohort 2: Non-small cell lung cancer (stage IB-III):; Cohort 2A: Resectable OR Cohort 2B: Unresectable,
- Cohort 3: Invasive breast carcinoma with hormone receptor (e.g. estrogen receptor (ER) and progesterone receptor (PR) expression) and human epidermal growth factor receptor 2 (HER2) status known and one the following:; Cohort 3A: High-risk2 HER2+ breast cancer (any ER, PR status allowed) OR Cohort 3B: High-risk2 triple negative breast cancer (TNBC) OR Cohort 3C: High-risk3 HR-positive/HER2-negative invasive breast carcinoma,
- Cohort 4: Stage IIB-III cutaneous melanoma or limited (resectable) stage IV melanoma treated with curative intent,
- Cohort 5: Esophageal or gastroesophageal junction carcinoma (stage II-III),
- Cohort 6: Gastric adenocarcinoma (stage II-III),
- Cohort 7: Pancreatic adenocarcinoma that is has been surgically resected or is eligible for surgical resection,
- Cohort 8: Cohort 8: Invasive squamous cell carcinoma of the head and neck (includes stage I-IVB HPV-negative or stage III-IVB HPV-positive oral cavity, oropharynx, hypopharynx, larynx, nasopharynx, nasal cavity, or paranasal sinus),
- Cohort 9: High-risk epithelial ovarian or Fallopian tube carcinoma (defined as FIGO stage IC-III, stage IA-IB that has high grade, carcinosarcoma, or clear cell histology),
- Cohort 10: Endometrial carcinoma (2023 FIGO Stage II-III or 2023 FIGO Stage IC or any Stage I with p53 abnormal molecular subtype),
- Cohort 11: High-risk renal cell carcinoma (Defined as high grade (grade 3-4) stage II, stage III or limited stage IV (meaning metastatic sites are considered treatable with curative intent)
- Cohort 12: Colorectal adenocarcinoma Cohort 12A: Pathologically confirmed adenocarcinoma of the rectum (located up to 15 cm from the anal verge) that is undergoing or underwent a preoperative chemotherapy-or immunotherapy- containing regimen OR Cohort 12B: Colon adenocarcinoma (stage II-III)
Who cannot take part
- History of allogeneic organ or tissue transplant
- Index cancer has predominantly neuroendocrine histology
- History of another primary cancer diagnosed within 3 years of enrollment, with the exception that in situ cancers, non-melanoma skin carcinomas, localized low- or intermediate risk prostate cancers (defined as cancers confined to the prostate with Gleason score of 7 or lower and prostate-specific antigen (PSA) of less than 20), and stage I papillary thyroid carcinoma, and participants with bilateral/multifocal tumors within the same organ (for example, bilateral breast cancer) are allowed if diagnosed within 3 years of enrollment
- Known distant metastasis at time of enrollment (with the exception of participants with limited/resectable stage IV cutaneous melanoma or RCC)
Where in United States
Also in 4 other countries, 24 sites
- ThedaCare Regional Cancer CenterAppleton, United StatesContact: Sarah LoetherTaking people
- University of ColoradoAurora, United StatesContact: Emily HarperTaking people
- University of Alabama at BirminghamBirmingham, United StatesContact: Susan BinkleyTaking people
- Massachusetts General HospitalBoston, United StatesContact: Clinical Trial OperationsNo longer taking part
- Crozer-Keystone Health SystemBroomall, United StatesContact: Clinical Trial OperationsNo longer taking part
- Ironwood Cancer & Research CentersChandler, United StatesContact: Charmaine MetrolisTaking people
- UNC- Chapel HillChapel Hill, United StatesContact: Adrianna WarnerTaking people
- The Christ Hospital Cancer CenterCincinnati, United StatesContact: Clinical Trial OperationsNo longer taking part
- Cleveland ClinicCleveland, United StatesContact: Gabby RedrickTaking people
- UT Southwestern Medical CenterDallas, United StatesContact: Molly McGuireTaking people
- Astera Cancer CareEast Brunswick, United StatesContact: Percy YeungTaking people
- DHR Health Advance Care CenterEdinburg, United StatesContact: Edgar Lopez PachecoTaking people
- The Center for Cancer and Blood DisordersForth Worth, United StatesContact: Anna Rose AbanganTaking people
- Cancer & Hematology Centers of Western MichiganGrand Rapids, United StatesContact: Angela NewmanTaking people
- Memorial Healthcare SystemHollywood, United StatesContact: Machelle SeymourTaking people
- Genesis Cancer CenterHot Springs, United StatesContact: Clinical Trial OperationsNo longer taking part
- University of California San DiegoLa Jolla, United StatesContact: Susanna LeeTaking people
- The Oncology Institute of Hope & InnovationLakeland, United StatesContact: Chantelle PassmoreTaking people
- Central Maine Medical CenterLewiston, United StatesContact: Clinical Trial OperationsNo longer taking part
- Carolina Urologic Research CenterMyrtle Beach, United StatesContact: Angela BuffkinTaking people
- Tulane Cancer CenterNew Orleans, United StatesContact: Minqi HaungTaking people
- Icahn School of Medicine at Mount SinaiNew York, United StatesContact: Clinical Trial OperationsNo longer taking part
- Hoag Memorial Hospital PresbyterianNewport Beach, United StatesContact: Alexandria AdamsTaking people
- University of PennsylvaniaPhiladelphia, United StatesContact: Willdragon WangTaking people
- Redwood CityRedwood City, United StatesContact: Clinical Trial OperationsTaking people
- Mayo Clinic - RochesterRochester, United StatesContact: Renee BradshawTaking people
- Carolina Blood and Cancer Care AssociatesRock Hill, United StatesContact: Clinical Trial OperationsNo longer taking part
- Sutter Institute for Medical ResearchSacramento, United StatesContact: Clinical Trial OperationsNo longer taking part
- Utah Cancer SpecialistsSalt Lake City, United StatesContact: Angela NuttallTaking people
- The University of Texas Health Science Center at San AntonioSan Antonio, United StatesContact: James DennoTaking people
- Christus Highland/ BoniolShreveport, United StatesContact: Cynthia AllgoodTaking people
- Toledo Clinic Cancer CenterToledo, United StatesContact: Jennifer MartinezTaking people
- WellSpan Medical Oncology & Hematology at York Cancer CenterYork, United StatesContact: Clarrisa VegaTaking people
About the trial
What the trial wants to find out
The purpose of ORACLE is to demonstrate the ability of a novel ctDNA assay developed by Guardant Health to detect recurrence in individuals treated for early-stage solid tumors. It is necessary that ctDNA test results are linked to clinical outcomes in order to demonstrate clinical validity for recurrence detection and explore its value in a healthcare environment subject to cost containment.
The 12 groups in the trial
- Cohort 1: Muscle invasive carcinoma of the bladder, ureter, or renal pelvis (stage II-III)
Treatment: Guardant Reveal
- Cohort 2: Non-small cell lung cancer (stage IB-III)
Cohort 2A: Resectable Cohort 2B: Unresectable
Treatment: Guardant Reveal
- Cohort 3: Invasive breast carcinoma with hormone receptor and HER2 status
Cohort 3A: High-risk HER2+ breast cancer (any ER, PR status allowed); defined as having stage II-III or having residual invasive disease (i.e. non-pathologic complete response) following a neoadjuvant chemotherapy-containing regimen OR Cohort 3B: High-risk triple negative breast cancer (TNBC); defined as having stage II-III or having residual invasive disease (i.e. non-pathologic complete response) following a neoadjuvant chemotherapy-containing regimen OR Cohort 3C: HR-positive/HER2-negative invasive breast carcinoma with either \>4 positive axillary lymph nodes or 1-3 positive axillary lymph nodes and at least one of the following: tumor size \>5 cm, histologic grade 3, or validated gene expression assay indicating high recurrence risk (OncotypeDx score \> 26, MammaPrint high, ProSigna high, EndoPredict high)
Treatment: Guardant Reveal
- Cohort 4: Stage IIB-III cutaneous melanoma or limited (resectable) stage IV melanoma
Treatment: Guardant Reveal
- Cohort 5: Esophageal or gastroesophageal junction carcinoma (stage II-III)
Treatment: Guardant Reveal
- Cohort 6: Gastric adenocarcinoma (stage II-III)
Treatment: Guardant Reveal
- Cohort 7: Pancreatic adenocarcinoma
That is has been surgically resected or is eligible for surgical resection
Treatment: Guardant Reveal
- Cohort 8: Invasive squamous cell carcinoma of the head and neck
Includes stage I-IVB HPV-negative or stage III-IVB HPV-positive oral cavity, oropharynx, hypopharynx, larynx, nasopharynx, nasal cavity, or paranasal sinus
Treatment: Guardant Reveal
- Cohort 9: High-risk epithelial ovarian or Fallopian tube carcinoma
Defined as FIGO stage IC-III, stage IA-IB that has high grade, carcinosarcoma, or clear cell histology
Treatment: Guardant Reveal
- Cohort 10: Endometrial carcinoma
Defined as 2023 FIGO Stage II-III or 2023 FIGO Stage IC or any Stage I with p53 abnormal molecular subtype
Treatment: Guardant Reveal
- Cohort 11: High-risk renal cell carcinoma
Defined as high grade (grade 3-4) stage II, stage III or limited stage IV (meaning metastatic sites are considered treatable with curative intent).
Treatment: Guardant Reveal
- Cohort 12: Colorectal adenocarcinoma
12A Rectal Adenocarcinoma: Pathologically confirmed adenocarcinoma of the rectum, located up to 15 cm from the anal verge that is undergoing or underwent a preoperative chemotherapy- or immunotherapy-containing regimen 12B Colon Adenocarcinoma: stage II-III
Treatment: Guardant Reveal
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- Plain-language title
- Blood test to detect returning cancer after treatment of early-stage solid tumorsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 14 September 2026